Back to top
more

Krystal Biotech (KRYS)

(Delayed Data from NSDQ)

$176.83 USD

176.83
1,549,911

+12.41 (7.55%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $176.80 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for KRYS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Krystal Biotech, Inc. [KRYS]

Reports for Purchase

Showing records 41 - 60 ( 68 total )

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

03/24/2021

Daily Note

Pages: 5

Nice Update on the Aesthetic Platform; B-VEC on Track to Complete Pivotal Enrollment in 1Q21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

03/01/2021

Company Report

Pages: 9

2020 Results; Key Updates Upcoming Across All Programs; Target Upped to $103

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

01/08/2021

Company Report

Pages: 8

Key Milestones Across All Programs Are Set to Drive Value in 2021; Target Increased to $84

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

11/10/2020

Company Report

Pages: 7

3Q20 Results; Progress Continues Towards Key Updates Across all Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

08/25/2020

Daily Note

Pages: 6

KB301 Hits the Clinic as Expected

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

08/10/2020

Company Report

Pages: 7

2Q20 Results; KB-105 Begins Phase 2; Pivotal Study and Pipeline Development Continue

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

07/29/2020

Company Report

Pages: 7

B-VEC Officially Goes Pivotal; Topline Data Expected in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

05/14/2020

Company Report

Pages: 8

KB105 Delivers Initial Clinical Validation at SID

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

05/13/2020

Company Report

Pages: 7

Introducing KB407; CFTR Null Mutation Could Be Addressed for Cystic Fibrosis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

05/04/2020

Company Report

Pages: 7

1Q20 Results; B-VEC Waiting to Begin Pivotal While Pipeline Jumps Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

04/30/2020

Company Report

Pages: 6

B-VEC Phase 3 Is Ready to Just Press Play; Pipeline Expansion Waits for Nobody; CF Added to Fray

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

03/10/2020

Company Report

Pages: 7

2019 Results; Pivotal Study in RDEB Slated to Begin in 1H20; Target Increased to $68

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

11/04/2019

Company Report

Pages: 7

3Q19 Results; Dotting Some "i''s" Ahead of Phase 3 Start; Data Support Successful Outcome

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

10/29/2019

Company Report

Pages: 6

Final KB-103 (now B-VEC) Phase 1/2 Data Solidifies Confidence; Pivotal Expected to Begin Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

09/04/2019

Daily Note

Pages: 3

KB105 Begins Phase 1/2 Study in Patients With ARCI

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

08/06/2019

Company Report

Pages: 7

2Q19 Results and Highlights; KB103 Going Pivotal and Pipeline Pushes Forward; Target Increased to $59

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

06/24/2019

Company Report

Pages: 6

KB103 Delivers on Efficacy and Safety as Expected and Marches Steady to Pivotal; Target Increased to $56

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

06/14/2019

Daily Note

Pages: 4

KB105 Moving Forward, as Planned, With IND Submission to the FDA; Phase 1/2 Clinical Trial Expected to Begin in 2H19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Krystal Biotech, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

05/24/2019

Company Report

Pages: 7

Management Dinner Further Preps for Key KB103 Update; Target Increased to $38

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party